Home › Funds › Pivotal bioVenture Partners Investment Advisor LLC › MPLT
Pivotal bioVenture Partners Investment Advisor LLC position in MPLT
MAPLIGHT THERAPEUTICS INC · Health Care
Pivotal bioVenture Partners Investment Advisor LLC reported holding 611,446 shares of MPLT (MAPLIGHT THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$6.2M, representing 2.54% of its reported portfolio and ranking #11 among its reported holdings. Pivotal bioVenture Partners Investment Advisor LLC has disclosed MPLT holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Pivotal bioVenture Partners Investment Advisor LLC's MPLT position evolved
Pivotal bioVenture Partners Investment Advisor LLC first disclosed a stake in MPLT in Q4 2025 at 611,447 shares (US$10.7M). The position peaked in Q2 2026 at 611,446 shares, worth US$21.9M. Across 4 filings, Pivotal bioVenture Partners Investment Advisor LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 611,446 shares valued at US$6.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 611.45K | $10.74M | New |
| Q1 2026 | 611.45K | $12.43M | Hold |
| Q2 2026 | 611.45K | $21.91M | Hold |
| Q3 2026 | 611.45K | $6.23M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MPLT and 13F data
MPLT (MAPLIGHT THERAPEUTICS INC) is a Health Care company. 97 other funds we track also report a position in MPLT — the largest reported positions include Novo Holdings A/S (US$132.1M), FCPM III SERVICES B.V. (US$115.6M), 5AM Venture Management, LLC (US$34.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MPLT
- Novo Holdings A/S 3.69M sh · $132.13M · Q2 2026
- FCPM III SERVICES B.V. 3.23M sh · $115.63M · Q2 2026
- 5AM Venture Management, LLC 950.01K sh · $34.05M · Q2 2026
- Paradigm Biocapital Advisors LP 685.85K sh · $24.58M · Q2 2026
- Nan Fung Group Holdings Ltd 2.30M sh · $23.44M · Q3 2026
- Velan Capital Investment Management LP 492.89K sh · $17.67M · Q2 2026
- Sanofi 912.04K sh · $9.29M · Q3 2026
- DAFNA Capital Management LLC 171.01K sh · $6.13M · Q2 2026
- Blue Owl Capital Holdings LP 556.37K sh · $5.67M · Q3 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 125.43K sh · $4.50M · Q2 2026
- STEMPOINT CAPITAL LP 106.91K sh · $3.83M · Q2 2026
More on Pivotal bioVenture Partners Investment Advisor LLC
FAQ
How long has Pivotal bioVenture Partners Investment Advisor LLC held MPLT?
Pivotal bioVenture Partners Investment Advisor LLC has disclosed MPLT holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Pivotal bioVenture Partners Investment Advisor LLC's current position in MPLT?
As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 611.45K shares of MPLT (MAPLIGHT THERAPEUTICS INC), valued at $6.23M, representing 2.54% of its reported portfolio and ranking #11.
Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling MPLT?
In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC held unchanged its position in MPLT. The position peaked in Q2 2026 at 611.45K shares.
Which other funds hold MPLT?
Other major institutional holders of MPLT include Novo Holdings A/S, FCPM III SERVICES B.V., 5AM Venture Management, LLC, among 97 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.